Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts

Cardiovascular Research

Volumn 88, Issue 3, 2010, Pages 424-433

  Tang, Mingxin ^a,d   Li, Jie ^a   Huang, Wei ^a,e   Su, Huabo ^a   Liang, Qiangrong ^b   Tian, Zongwen ^a   Horak, Kathleen M ^a   Molkentin, Jeffery D ^c   Wang, Xuejun ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b SANFORD RESEARCH   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Calcineurin; Cardiac remodelling; Desmin related cardiomyopathy; Nuclear factors of activated T cells; Proteasome

Indexed keywords

BORTEZOMIB; CALCINEURIN; DESMIN; MG262; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CARDIOMYOPATHY; CELL CULTURE; CELL SHAPE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE TRANSLOCATION; HEART DILATATION; HEART FAILURE; HEART MUSCLE CELL; HEART STRESS; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEASOME FUNCTIONAL INSUFFICIENCY; RANDOMIZED CONTROLLED TRIAL; RAT; REPORTER GENE; SHAM PROCEDURE; SIGNAL TRANSDUCTION; TRANSACTIVATION; WESTERN BLOTTING;

ANIMALS; BORONIC ACIDS; CALCINEURIN; CELLS, CULTURED; DESMIN; HEART FAILURE; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 77957356238     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq217     Document Type: Article

References (43)

1. Su H, Wang X. The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovasc Res 2010;85:253-262.
2. Vignier N, Schlossarek S, Fraysse B, Mearini G, Kramer E, Pointu H et al. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res 2009;105:239-248.
3. Mearini G, Schlossarek S, Willis MS, Carrier L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 2008;1782:749-763.
4. Willis MS, Townley-Tilson WH, Kang EY, Homeister JW, Patterson C. Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res 2010;106: 463-478.
5. Chen Q, Liu JB, Horak KM, Zheng H, Kumarapeli AR, Li J et al. Intrasarcoplasmic amy-loidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res 2005;97:1018-1026.
6. Tsukamoto O, Minamino T, Kitakaze M. Functional alterations of cardiac proteasomes under physiological and pathological conditions. Cardiovasc Res 2010;85:339-346.
7. Liu J, Chen Q, Huang W, Horak KM, Zheng H, Mestril R et al. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J 2006;20: 362-364.
8. Wang X, Su H, Ranek MJ. Protein quality control and degradation in cardiomyocytes. J Mol Cell Cardiol 2008;45:11-27.
9. Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 2008;88:219-222.
10. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 2006;6:129.
11. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C et al. Unexpected cardi-otoxicity in haematological bortezomib treated patients. Br J Haematol 2007;138: 396-397.
12. Liu J, Tang M, Mestril R, Wang X. Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. J Mol Cell Cardiol 2006;40:451-454.
13. Wang X, Osinska H, Klevitsky R, Gerdes AM, Nieman M, Lorenz J et al. Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ Res 2001;89:84-91.
14. Wang X, Osinska H, Dorn GW 2nd, Nieman M, Lorenz JN, Gerdes AM et al. Mouse model of desmin-related cardiomyopathy. Circulation 2001;103:2402-2407.
15. Rappaport L, Contard F, Samuel JL, Delcayre C, Marotte F, Tome F et al. Storage of phosphorylated desmin in a familial myopathy. FEBS Lett 1988;231:421-425.
16. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000;342:770-780. (Pubitemid 30151921)
17. Vicart P, Caron A, Guicheney P, Li Z, Prevost MC, Faure A et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 1998;20:92-95.
18. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A et al. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci USA 2004; 101:10132-10136.
19. Tannous P, Zhu H, Nemchenko A, Berry JM, Johnstone JL, Shelton JM et al. Intracellu-lar protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation 2008;117:3070-3078.
20. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93:215-228. (Pubitemid 28180855)
21. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-600.
22. Burkard N, Becher J, Heindl C, Neyses L, Schuh K, Ritter O. Targeted proteolysis sustains calcineurin activation. Circulation 2005;111:1045-1053.
23. Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 2004;114:1058-1071.
24. Fan Y, Xie P, Zhang T, Zhang H, Gu D, She M et al. Regulation of the stability and transcriptional activity of NFATc4 by ubiquitination. FEBS Lett 2008;582:4008-4014.
25. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004;94:110-118.
26. Hunton DL, Lucchesi PA, Pang Y, Cheng X, Dell'Italia LJ, Marchase RB. Capacitative calcium entry contributes to nuclear factor of activated T-cells nuclear translocation and hypertrophy in cardiomyocytes. J Biol Chem 2002;277:14266-14273.
27. Kumarapeli AR, Su H, Huang W, Tang M, Zheng H, Horak KM et al. Alpha B-crystallin suppresses pressure overload cardiac hypertrophy. Circ Res 2008;103:1473-1482.
28. Zhou YY, Wang SQ, Zhu WZ, Chruscinski A, Kobilka BK, Ziman B et al. Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. Am J Physiol Heart Circ Physiol 2000;279:H429-H436.
29. Huber JM, Tagwerker A, Heininger D, Mayer G, Rosenkranz AR, Eller K. The protea-some inhibitor bortezomib aggravates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2009;297:F451-F460.
30. Williamson MJ, Silva MD, Terkelsen J, Robertson R, Yu L, Xia C et al. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bor-tezomib in mouse xenograft models. Mol Cancer Ther 2009;8:3234-3243.
31. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-4427.
32. Li F, Wang X, Yi XP, Gerdes AM. Structural basis of ventricular remodeling: role of the myocyte. Curr Heart Fail Rep 2004;1:5-8.
33. Oka T, Dai YS, Molkentin JD. Regulation of calcineurin through transcriptional induction of the calcineurin A beta promoter in vitro and in vivo. Mol Cell Biol 2005;25: 6649-6659.
34. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001;103:670-677.
35. Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2000;97: 1196-1201.
36. Ni YG, Berenji K, Wang N, Oh M, Sachan N, Dey A et al. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation 2006;114: 1159-1168.
37. Kassiotis C, Ballal K, Wellnitz K, Vela D, Gong M, Salazar R et al. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation 2009; 120:S191-S197.
38. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 2008;51:302-308.
39. Dong X, Liu J, Zheng H, Glasford JW, Huang W, Chen QH et al. In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes. Am J Physiol Heart Circ Physiol 2004;287:H1417-H1425.
40. Chu G, Carr AN, Young KB, Lester JW, Yatani A, Sanbe A et al. Enhanced myocyte contractility and Ca2+ handling in a calcineurin transgenic model of heart failure. Cardiovasc Res 2002;54:105-116.
41. Hedhli N, Depre C. Proteasome inhibitors and cardiac cell growth. Cardiovasc Res 2010;85:321-329.
42. Tannous P, Zhu H, Johnstone JL, Shelton JM, Rajasekaran NS, Benjamin IJ et al. Autop-hagy is an adaptive response in desmin-related cardiomyopathy. Proc Natl Acad Sci USA 2008;105:9745-9750.
43. Rothermel BA, Hill JA. The heart of autophagy: deconstructing cardiac proteotoxicity. Autophagy 2008;4:932-935.